Subependymal giant cell astrocytoma

Common Name(s)

Subependymal giant cell astrocytoma

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Subependymal giant cell astrocytoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Subependymal giant cell astrocytoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Subependymal giant cell astrocytoma" returned 24 free, full-text research articles on human participants. First 3 results:

Everolimus for subependymal giant cell astrocytoma: 5-year final analysis.
 

Author(s): David N Franz, Karen Agricola, Maxwell Mays, Cindy Tudor, Marguerite M Care, Katherine Holland-Bouley, Noah Berkowitz, Sara Miao, Séverine Peyrard, Darcy A Krueger

Journal: Ann. Neurol.. 2015 Dec;78(6):929-38.

 

To analyze the cumulative efficacy and safety of everolimus in treating subependymal giant cell astrocytomas (SEGA) associated with tuberous sclerosis complex (TSC) from an open-label phase II study (NCT00411619). Updated data became available from the conclusion of the extension ...

Last Updated: 15 Jan 2016

Go To URL
Erk activation as a possible mechanism of transformation of subependymal nodule into subependymal giant cell astrocytoma.
 

Author(s): M Siedlecka, S Szlufik, W Grajkowska, M Roszkowski, J Jóźwiak

Journal: Folia Neuropathol. 2015 ;53(1):8-14.

 

Subependymal nodule (SEN) and subependymal giant cell astrocytoma (SEGA) are brain lesions frequently found in tuberous sclerosis (TS). As about 10-15% of SENs enlarge and transform into SEGAs, we examined here the possible mechanism of the phenomenon.

Last Updated: 27 Apr 2015

Go To URL
An unusually aggressive clinical behavior in a case of atypical subependymal giant cell astrocytoma.
 

Author(s): Devi Prasad Patra, Pravin Salunke, Debajyoti Chatterjee, R K Vasishta

Journal: Neurol India. ;62(5):546-8.

 

Last Updated: 12 Nov 2014

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Subependymal giant cell astrocytoma" returned 2 free, full-text review articles on human participants. First 3 results:

Subependymal giant cell astrocytoma (SEGA): a case report and review of the literature.
 

Author(s): Layla Tahiri Elousrouti, Meryem Lamchahab, Nawal Bougtoub, Hinde Elfatemi, Laila Chbani, Taoufik Harmouch, Mustapha Maaroufi, Afaf Amarti Riffi

Journal:

 

Subependymal giant cell astrocytoma is a rare tumor that occurs in the wall of the lateral ventricle and foramen of Monro and, rarely, in the third ventricle. It is one of the intracranial lesions found in tuberous sclerosis complex (which include subependymal nodules, cortical tubers, ...

Last Updated: 10 Feb 2016

Go To URL
Everolimus tablets for patients with subependymal giant cell astrocytoma.
 

Author(s): Scott G Turner, Katherine B Peters, James J Vredenburgh, Annick Desjardins, Henry S Friedman, David A Reardon

Journal: Expert Opin Pharmacother. 2011 Oct;12(14):2265-9.

 

Better understanding of aberrantly active molecular pathways in tumors offers potential to develop more specific and less toxic therapies. Abnormal mammalian target of rapamycin (mTOR) complex signaling and defects in TSC1 and TSC2 have been associated with the development of subependymal ...

Last Updated: 7 Sep 2011

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
 

Status: Recruiting

Condition Summary: Adult Anaplastic Astrocytoma; Adult Anaplastic Ependymoma; Adult Anaplastic Oligodendroglioma; Adult Brain Stem Glioma; Adult Diffuse Astrocytoma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Adult Oligodendroglioma; Adult Pilocytic Astrocytoma; Adult Pineal Gland Astrocytoma; Adult Subependymal Giant Cell Astrocytoma; Recurrent Adult Brain Tumor

 

Last Updated: 19 Oct 2016

Go to URL
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
 

Status: Recruiting

Condition Summary: Brain and Central Nervous System Tumors; Intraocular Melanoma; Lung Cancer; Melanoma (Skin); Metastatic Cancer; Neuroblastoma; Ovarian Cancer; Retinoblastoma; Sarcoma; Small Intestine Cancer

 

Last Updated: 8 Aug 2016

Go to URL
Everolimus in Treating Patients With Recurrent or Progressive Low-Grade Glioma
 

Status: Recruiting

Condition Summary: Brain Tumor

 

Last Updated: 27 May 2015

Go to URL